
Darren Woodside, Ph.D., is the Vice President for Research and Director of the Flow Cytometry and Imaging Core at the Texas Heart Institute. Show full bio
Dr. Woodside’s research centers around the role that cell adhesion plays in cardiovascular and autoimmune diseases, and the development of novel means to identify and treat these diseases. Prior to assuming the position of Vice President, he served as Associate Director of the Molecular Cardiology Research Laboratories at THI and Associate Director of Drug Discovery at Encysive Pharmaceuticals. He was awarded his Ph.D. from the University of Texas MD Anderson Cancer Center’s Department of Immunology and was a post-doctoral fellow at The Scripps Research Institute.
He has authored numerous publications, served on Editorial Review Boards, and currently chairs the NIH Innovative Immunology Study Section.
Texas Heart Institute Positions
- Vice President, Research
- Director, Flow Cytometry and Imaging, Molecular Cardiology Research
Interests
- Inflammation
- Non-invasive diagnostic imaging technologies
Education
-
Undergraduate:
Queen's University at Kingston
-
Postgraduate:
University of Texas MD Anderson Cancer Center, Graduate School of Biomedical Sciences
-
Fellowships:
The Scripps Research Institute
Honors, Awards and Memberships
Publications
Recent News

Cell adhesion research could lead to a new pain alternative for patients with inflammatory conditions
Today more than 30 million patients suffer from painful inflammatory conditions. Prescription opioid pain relievers are commonly prescribed for these...

THI discovery targets inflammatory disease for patients suffering from IBD
Grant from the NIH NIDDK to Advance Collaboration to Develop Treatments for Inflammatory Disease HOUSTON, TX, November 10, 2020 –...

Discovery in the molecular cardiology research labs could improve immuno-oncology drugs, covid, and influenza vaccines
Texas Heart Institute scientists illuminated a molecular pathway that could one day strengthen the immune response to immunotherapies. The first-in-human...